Argyrophilic grain disease: An underestimated tauopathy. by Rodriguez, Roberta Diehl & Grinberg, Lea Tenenholz
UCSF
UC San Francisco Previously Published Works
Title
















eScholarship.org Powered by the California Digital Library
University of California
Dement Neuropsychol 2015 March;9(1):2-8
2
Views & Reviews
Argyrophilic grain disease    Rodriguez RD, Grinberg LT
Argyrophilic grain disease
An underestimated tauopathy
Roberta Diehl Rodriguez1, Lea Tenenholz Grinberg2
ABSTRACT. Argyrophilic grain disease (AGD) is an under-recognized, distinct, highly frequent sporadic tauopathy, with a 
prevalence reaching 31.3% in centenarians. The most common AGD manifestation is slowly progressive amnestic mild 
cognitive impairment, accompanied by a high prevalence of neuropsychiatric symptoms. AGD diagnosis can only be achieved 
postmortem based on the finding of its three main pathologic features: argyrophilic grains, oligodendrocytic coiled bodies 
and neuronal pretangles. AGD is frequently seen together with Alzheimer’s disease-type pathology or in association with 
other neurodegenerative diseases. Recent studies suggest that AGD may be a defense mechanism against the spread of 
other neuropathological entities, particularly Alzheimer’s disease. This review aims to provide an in-depth overview of the 
current understanding on AGD.
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DOENÇA COM GRÃOS ARGIROFÍLICOS: UMA TAUPATIA SUBESTIMADA
RESUMO. A doença com grãos argirofílicos (DGA) é uma taupatia esporádica distinta, bastante frequente, porém pouco 
reconhecida com uma prevalência atingindo 31,3% em centenários. A manifestação clínica mais comum da DGA é de um 
comprometimento cognitivo de lenta evolução associado a uma alta prevalência de sintomas psiquiátricos. O diagnóstico de 
DGA é possível somente com a análise do encéfalo post-mortem com os achados das três principais alterações patológicas: 
grãos argirofílicos, corpúsculos em embrião e pré- emaranhados neuronais. A DGA é, frequentemente, associada com 
alterações patológicas do tipo Alzheimer. Estudos recentes sugerem a AGD como um mecanismo de defesa contra a 
propagação de outras alterações neuropatológicas, em especial a doença de Alzheimer. Essa revisão almeja proporcionar 
uma visão geral do conhecimento atual sobre a DGA.
Palavras-chave: doença com grãos argirofílicos, demência, taupatias, doenças neurodegenerativas, patologia, post-mortem.
INTRODUCTION
Argyrophilic grain disease (AGD) is highly frequent, but still under-recognized neu-
rodegenerative condition.1 AGD has proven 
the second-most-common neurodegenera-
tive disease after Alzheimer’s disease (AD) 
in several studies.2-6 The incidence of AGD 
increases significantly with age and its preva-
lence has been estimated to range from 9.3% 
in 65 year-olds to 31.3% in centenarians.4,7-9 
Although AGD is more prevalent in older 
individuals, it is not exclusively seen in the 
elderly. Ishihara et al. reported a 54-year-old 
man with a neuropathological diagnosis of 
AGD presenting frontotemporal dementia at 
age 49 years of age. Saito et al. detected AGD 
in a 56-year-old man from a series of 1,405 
autopsies.6,10 In the series of the Brain Bank 
of the Brazilian Aging Brain Study Group, 
6.7% of individuals aged between 50 and 60 
had AGD.11 
AGD was first reported in 1987, by Braak 
and co-workers as a progressive, late-onset 
neurodegenerative disease characterized by 
small spindle- or comma-shaped, silver stain 
positive lesions in neuronal processes, re-
ferred to as argyrophilic grains (AG).12 Sub-
sequently, studies revealed hyperphosphory-
lated-tau protein as a major AG component. 
AGD is frequently seen overlapping with AD 
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pathology, making it even more difficult to investigate 
the role of AGD in cognition.2,13-15 Consequently, many 
have recognized AGD as a distinctive pathological enti-
ty only recently.16-23 The first descriptions characterized 
AGD as a novel neuropathological entity in patients 
with progressive late-onset dementia who lacked suffi-
cient numbers of Alzheimer-type lesions to warrant the 
morphological diagnosis of Alzheimer disease,12,24,25 as-
sociated with dementia or otherwise.4,5,26-33
At any rate, AGD is virtually unknown to the clini-
cal community because most cases do not present any 
known distinctive clinical symptoms.4,5,9,26-29,31-34
Clinical presentation. Clinicopathological studies failed to 
show a distinctive clinical or imaging phenotype associ-
ated with AGD, and currently, diagnosis is only possible 
through postmortem brain analysis.17
A very slowly progressive mild cognitive impairment 
(MCI) is the most common AGD manifestation.4,13,36 
Saito et al. in a study investigating pathological changes 
underlying MCI, investigated 545 serial autopsy cases 
from a general geriatric hospital. They found neuro-
degenerative pathology in 57% of MCI cases (19% AD 
and 18% AGD). The authors then extended the study to 
also include dementia cases and found AD in 45% and 
AGD in 18% of the cases. Their findings suggested that a 
higher relative frequency of beta-amyloid-independent 
tauopathies, such as AGD, in the MCI group is probably 
related to the more benign course of such diseases.36
Some studies have associated AGD with neuropsychi-
atric symptoms. AGD subjects present more personality 
changes and emotional imbalance preceding memory 
failure than age-matched controls.10,13,37-39 There is evi-
dences that at early and mild stages of the disease, emo-
tional and personality changes are the dominant clinical 
features of AGD, reflecting the prominent involvement 
of the limbic system.6,40,41 Saito et al. reported that AGs 
are initially found in the temporo-amygdaloid junction, 
and that the distribution of AGs followed a stereotypic 
regional pattern of spread reflecting an antero-posterior 
gradient in putative AGD progression. A study compar-
ing Parkinson’s disease patients with and without AGD, 
and studies showing a high prevalence of AGD in indi-
viduals with late-onset schizophrenia and delusional 
disorders, corroborate the association of AGD with psy-
chiatric symptoms.42,43 Asaoka et al. reported an AGD 
case exhibiting delusions and hallucinations at clinical 
presentation.37
A few reports implicate AGD as the underlying con-
dition in patients featuring clinical frontotemporal de-
mentia. In such cases, AGD pathology is widespread 
in the brain, as opposed to the majority of AGD cases 
where involvement is restricted to limbic structures. 
Tsuchiya et al. reported an 89-year-old female featur-
ing temporal frontotemporal dementia (previously 
known as Pick’s disease), amnesia, wandering, person-
ality changes characterized by unusual rude, stubborn 
and egocentric behavior.40 Maurage et al. reported two 
cases fulfilling revised criteria for possible behavioral-
variant frontotemporal dementia (bvFTD): a 76-year-
old female with cognitive impairment, obsession, apa-
thy, carbohydrate craving; and a 79-year-old female with 
cognitive slowing, apathy, memory impairment, logor-
rhea and carbohydrate craving.44,45 Finally, Ishihara et 
al. described a 54-year-old male presenting personality 
changes and abnormal stereotypical behavior, disinhibi-
tion and environment-dependent behavior characteriz-
ing bvFTD. All these cases presented overlapping mild 
Alzheimer-type pathology.10
AGD can also be present in patients without cogni-
tive impairment. Knopman et al. showed AGD in 31% of 
a series of cognitively normal subjects.46 The anatomical 
substrate for cognitive impairment in AGD is unclear 
and studies have implicated the entorhinal cortex, hip-
pocampus, temporal association cortex and amygdala.47 
Tolnay et al. examined the limbic area in 19 demented 
patients with AGD and 16 non-demented patients with 
AGD. They demonstrated that the caudal part of hippo-
campal sector CA1 was found to be significantly more 
affected in demented AGD than in non-demented AGD. 
On the contrary, AG burden in rostral CA1 was similar 
in both demented and non-demented cases, suggesting 
that early subclinical lesions may begin in the anterior 
part of the hippocampal formation.9 Recently, the se-
vere degeneration of the ambient gyrus was associated 
with the development of dementia in AGD cases.41
Biochemical features. Tau is the major neuronal microtu-
bule-associated protein (MAP) encoded by the micro-
tubule-associated protein gene (MAPT). The tau gene 
is located at chromosome 17q21. In human adults, tau 
features six different isoforms due to alternative mRNA 
splicing of the exons 2, 3 and 10. The isoforms differ by 
the presence or absence of 29- or 58- aminoacid inserts 
in the N- terminal portion of the molecule or by the in-
clusion or otherwise of the 31 aminoacid repeat in the 
C- terminal part that is encoded by exon 10 of the MAPT. 
The inclusion of exon 10 generates an isoform with four 
microtubule-binding domains (4R), while the absence of 
this inclusion produces an isoform with three microtu-
bule binding domains (3R). In the adult healthy brain, 
there is an equal proportion of 3R and 4R forms.48,49 AGD 
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features predominant deposition of 4R-tau, as do pro-
gressive supranuclear palsy (PSP) and corticobasal de-
generation (CBD), whereas AD is characterized by the si-
multaneous presence of both 3R and 4R tau proteins.44,50
Tau protein promotes assembly of and stabilizes mi-
crotubules, one of the major structural components of 
the axonal transport and neurotransmission machinery. 
Abnormal phosphorylation of tau decreases its binding 
capacity to tubulin, leading to microtubule disorganiza-
tion with protein self-polymerization and aggregation. 
Tau phosphorylation is regulated by tau kinases, phos-
phatases and changes in its conformational state.48,51 
The mechanism by which tau protein becomes non-
functional remains unknown, but abnormal posttrans-
lational modifications other than phosphorylation may 
play an important role in this process.35,52 Recent studies 
have shown that increased tau acetylation could impair 
tau interactions with microtubules and contribute to 
tau aggregation. Evidence suggests that tau acetylation 
affects its degradation by polyubiquitination inhibi-
tion.22,35,53 Grinberg et al. demonstrated that tau acetyla-
tion is not present in AGD unlike in other common and 
rare tauopathies such as AD, Pick’s Disease, PSP, chronic 
traumatic encephalopathy and familial tauopathies. The 
lack of tau acetylation in AGD and the fact that hyper-
phosphorylation alone does not necessarily promote 
tau aggregation and cellular dysfunction suggest that 
AGD may be a protective mechanism against spread of 
other tauopathies rather than a harmful entity.22
Llieva et al. showed that the expression of apopto-
sis inducing factor, a multifunctional mitochondrial 
protein involved in oxidative stress and mitochondrial 
structure, is increased in both AGD and AD, but altered 
expression of components of the respiratory chain 
markers modulating mitochondrial biogenesis was se-
lectively affected in AGD.16
Neuropathological features. Macroscopically, AGD brains 
may be unchanged or only mildly atrophic, not differing 
from age-matched controls.4,5 Tolnay et al. only found 
mild temporal lobe atrophy in a few of their 41 AGD 
cases.9
Microscopically, AGD is characterized by three main 
pathologic features: [1] AGs, the pathologic hallmark 
lesion; [2] oligodendrocytic inclusions called coiled 
bodies, and [3] neuronal intracytoplasmic tau-positive 
granular inclusions called pretangles. Associated patho-
logic lesions include balloon neurons and bush-like as-
trocytes.8,19,47,50,54 Although coiled bodies and pretangles 
are not exclusive to AGD, they are positive for acetylated 
tau in all other tauopathies, yet not in AGD.22 
Argyrophilic grains: small spindle- or comma- shap-
ed structures found within neuronal processes mainly 
in the dendrites and dendritic spines (Figure 1).12,26,30,47 
AGs predominates in layers II and III of cerebral cor-
tex.12 They exhibit a typical distribution pattern, more 
abundant within the limbic system, mainly in the CA1 
sector of the hippocampus, subiculum, entorhinal and 
transentorhinal cortex, and adjacent temporal isocor-
tex.5,41 The amygdala and hypothalamic lateral nucleus 
are the most severely affected subcortical structures.5,25 
The size of AGs apparently increases with advancing 
stage, although areas with severe neuronal loss became 
devoid of AGs.41
AGs are not immunoreactive for antibody 12E8, 
against phosphorylated-tau at Ser 262/356, suggesting 
that different phosphorylation at this site is a late event 
occurring only in compact neurofibrillary lesions.55
Coiled bodies: oligodendrocytic inclusions are largely 
restricted to the white matter underlying the limbic 
cortex (Figure 1). These lesions are present in other 4R 
tauopathies such as PSP and CBD, but have a different 
anatomic distribution.50
Pretangles: these neuronal cytoplasmic tau-positive 
inclusions are Gallyas and ubiquitin-negative (Figure 1). 
Although they are distributed similarly to AGs,8,18 their 
presence is ubiquitous in the CA2 sector of the hippocam-
pus, a region extremely resistant to AD-type changes.9,30
Balloon neurons: are characterized by swelling of the 
perikarya and loss of Nissl substance of pyramidal neu-
rons. They are found in the brains of different neurode-
generative disorders, but not in normal brains (Figure 
1). In AGD, balloon neurons are more frequent in the 
amygdala and do not correlate with the density of AGs 
or the severity of associated lesions.34,54,56
Bush-like astrocytes: seen in the amygdala and ante-
rior entorhinal cortex of AGD cases (Figure 1). Despite 
being positive for hyperphosphorylated-tau, they do 
not display fibrils as evidenced by the absence of Gallyas 
positive staining.19 In addition, they are not a prominent 
feature of AGD.47,50,57 Botez et al. suggest that, together 
with other features, the presence of bush-like astrocytes 
may help to differentiate AGD from AD.19
Two different staging systems are available for stag-
ing AGD. Saito et al. suggest a 3-point system taking 
into consideration AGs, balloon neurons, bush-like as-
trocytes and coiled-bodies.6 The earliest changes are evi-
dent in the ambiens gyrus, followed by the anterior and 
posterior medial temporal lobe, and finally the septal 
area, anterior cingulate gyrus and insular cortex in later 
stages. Ferrer et al. propose a 4-point scale system con-
sidering AG distribution only. Involvement of anterior 
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entorhinal cortex, basolateral nuclei of amygdala and 
hypothalamic lateral tuberal nucleus represent early 
stages while neocortex and brainstem become involved 
in the last stage.47
Thal et al. studied the pattern of alterations in tem-
poro-entorhinal association neurons in seven brains 
(two with mild AD-related pathology without cognitive 
impairment, one severe AD-related pathology without 
cognitive impairment, one demented AD, and three 
AGD cases with dementia) using the postmortem Dil 
tracing technique. They showed a disconnection of asso-
ciation fibers between the entorhinal and the adjacent 
temporal neocortices in the AD case and in one non-
demented case with severe AD- related pathology. By 
contrast, all the AGD cases with cognitive impairment 
lacked obvious disconnection between the entorhinal 
and the temporal neocortices. However, the AGD cases 
displayed dendritic tree abnormalities when compared 
to the non-demented AD-related pathology and to the 
non-demented case with severe AD- related pathology. 
These findings suggest differences in the pattern of 
neurodegeneration between AGD and AD. Dementia in 
AD may be related to major anatomical disconnection, 
whereas dementia in AGD may be related to dendritic 
degeneration with preserved axonal connections.23,58
Other pathological changes: One study suggests prom-
inent superficial laminar spongiosis in cortical areas rich 
in AGs, a finding not confirmed in our observations.8
Because of the high overlap between AD-type pa-
thology and AGD, some advocate that the latter is part 
of the AD spectrum. However, fundamental differences 
can be noted between these two entities. [1] the AG 
spread pattern does not fit under the neurofibrillary 
staging system.59 Davis et al. found an age-associated 
increase of AGD in a study involving 20 AGD cases and 
controls. They found no association between AGs and 
AD-type neurofibrillary tangles or neuropil threads in 
the CA1 sector of the hippocampus. Finally, the number 
of neurofibrillary tangles and neuropil threads in AGD 
did not differ across the cognitive decline spectrum;60 
[2] Unlike in AD, the hippocampal sector CA2 and den-
tate gyrus are very vulnerable to AGD (Figure 1). Like-
wise, the hypothalamus shows a different vulnerability 
pattern to AGD with early and prominent involvement 
of lateral tuberal nuclei and relative resistance of tuber-
omammillary nuclei. In AD, the tuberomammillary nu-
clei are severely affected by neurofibrillary tangles.61,62 
The profile of Aβ deposition in AGD resembles that of 
cognitively normal elderly rather than of AD.31
Associated neurodegenerative diseases. AGs may resemble 
neuropil threads cut transversally, hampering diagno-
sis of AGD in patients harboring moderate-to-severe 
AD pathology.24,28 Braak and Braak, in a series of 2661 
unselected autopsies of subjects aged 27 to 96 years, ob-
served 125 cases of AGD as compared to 146 cases of 
AD stage V to VI. Most of the cases with AGD and severe 
progressive dementia showed only mild concomitant 
AD pathology corresponding to Braak stages I to III and 
only 12.5 % showed Braak stage V.4 The lower prevalence 
Figure 1. Tau pathological features in an AGD 
case immunostained with PHF-1 antibody. [A] 
Grains in the CA1 subfield of the hippocampus; 
[B] Pretangles with perinuclear halo in the CA2 
subfield of the hippocampus; [C] Coiled-body in 
the CA1 subfield of the hippocampus; [D] Balloon 
neuron in amygdala (arrow); [E] Bush-like astro-
cyte in amygdala; [F] Prominent involvement of 
CA2 subfield of the hippocampus with sparing of 
the CA1 subfield. Scale bars represent 50 µm in 
A, D, E; 20 µm in B,C and 200 µm in F.
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of AGD in AD cases with severe neurofibrillary pathol-
ogy may reflect difficulties in distinguishing the lesions.
Several studies have shown the association of AGD 
with other neurodegenerative diseases, including AD, 
Pick’s Disease, tangle-only dementia, Creutzeldt-Jacob 
disease, Parkinson’s Disease, Dementia with Lewy body, 
amyotrophic lateral sclerosis, PSP, and CBD.4,5,26,28,43,47,63 
AGD prevalence in these cases is apparently higher than 
expected for age-matched individuals. For instance, AGD 
is frequently observed in CBD (57.7% versus 30-40% age-
matched subjects) and PSP cases.6,7,28,46,64 These findings 
suggest that AGD shares common genetic or pathogenic 
features with PSP and CBD. Along the same lines, Tatsumi 
et al. described a frequency of 100% AGs in CBD cases.43 
Despite the high frequency of AG in PSP and CBD cases, a 
high prevalence of PSP and CBD pathology has not been 
observed in primary AGD cases, even in large cohorts.4,57
Recent studies have shown a high prevalence (40-
60%) of hyperphosphorylated transactive response 
DNA-binding protein with 43kD (TPD-43) in AGD cases, 
mainly in the limbic system.65,66 The clinical significance 
of TDP-43 pathology in the brains of patients with vari-
ous neurodegenerative disorders remains uncertain.67-71
Genetics. AGD is a predominantly sporadic disease. Re-
cent studies described two MAPT mutations causing 
pathological features consistent with AGD.20,72 A study 
published in 2008 demonstrated MAPT S305I muta-
tion in a case with neuropathological diagnosis of AGD, 
while the most recent report described S305S mutation 
in a Scandinavian family where two siblings had neu-
ropathological features resembling AGD. These reports 
describe common clinical features of early memory 
problems and behavioral changes. However, the S305S 
mutation was also associated with frontotemporal de-
mentia with parkinsonism and PSP in previous stud-
ies.73 Villela et al., in a study investigating DNA copy 
number variations (CNV) in 28 AGD cases, identified 
rare constitutive CNVs in these individuals. This find-
ing suggested a CNV at 17p13.2 as a strong candidate 
for causing AGD.74 Studies have demonstrated the role 
of CNV in the etiology of several neuropsychiatric dis-
orders.75 Unlike other 4R tauopathies such as PSP and 
CBD, there are controversies over the relationship of the 
tau H1 haplotype with positive and negative results.18,50
The apolipoprotein E (APOE) ε2 allele was associat-
ed with increased risk of AGD in one study, but further 
studies failed to confirm this relationship.64,76
AGD spread in experimental models. The progressive aggre-
gation of a particular protein in a stereotypical pattern 
is a common characteristic of all neurodegenerative dis-
orders. Recent studies showed that a group of proteins, 
including abnormal tau protein, can trigger self-propa-
gation in a prion-like fashion. These proteins share with 
prions the molecular properties of nucleation, templat-
ing, growth, multiplication and spread.77
Clavaguera et al. showed that intracerebral injection 
of brain extracts containing aggregated tau, including 
AGD, induces tauopathy in tau-transgenic host mice, and 
the induced tau lesions propagate systematically from 
the injection site to axonally connected areas suggest-
ing neuronal uptake, transport and release of tau seeds. 
However, these mice did not show signs of neurodegener-
ation, suggesting that the molecular species responsible 
for propagation and neurotoxicity could be different.78
Ahmed et al. hypothesized that the spread of tau 
protein aggregates depends on synaptic connectiv-
ity rather than spatial proximity.79 Additionally, in vitro 
studies showed that the intracellular entry of tau fila-
ments occurs through endocytosis.80,81
In a recent study, Dujardin et al. demonstrated a dif-
ferential tau spread between wild-type and mutant mice 
suggesting distinct mechanism for genetic and sporadic 
forms of tauopathies.82 Sanders et. al also demonstrated 
spread of abnormal tau in cell cultures exposed to ho-
mogenates of human brains with AGD.83
Conclusion. Clinicopathological studies have recognized 
AGD as a distinctive and highly frequent neurodegen-
erative disease. Aging is a well-established risk factor for 
AGD. To date, AGD diagnosis has been exclusively post-
mortem. The most typical clinical phenotype associated 
to AGD is slowly progressive mild cognitive impairment 
with a high frequency of neuropsychiatric symptoms that 
sometimes might precede the cognitive component. Ear-
ly and prominent involvement of the limbic system could 
explain the presence of neuropsychiatric symptoms.
The reasons why AGD does not develop with promi-
nent clinical features have yet to be clarified. Recent 
evidence of lack of tau acetylation in AGD suggest a 
protective role of this entity against spread of other 
neurodegenerative conditions, particularly Alzheimer’s 
disease and is a hypothesis currently being investigated.
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